Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

PaperCitations, authors & open-access status

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 2,952 citations, 2010 year and bronze oa status.

2,952
Citations
2010
Year
bronze
OA Status

Related on ScholarIQ

Julie R. Brahmer
Author
Journal of Clinical Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
Immunotherapy and Immune Responses
Topic
CAR-T cell therapy research
Topic
470M+ articles · free account